Kiromic BioPharma, Inc. using its proprietary DIAMOND artificial intelligence and data mining platform to develop cell therapies with a focus on immune-oncology, announces favorable safety results from the histopathology evaluation of a preclinical study of the pharmacology of KB-GDT-01 administered alone and in combination with a non-biological anti-tumor therapy in mice. The histopathology report, authored by a certified veterinary pathologist, revealed no adverse microscopic findings related to the administration of Deltacel alone or as part of the combination treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.4 USD | -27.05% | -26.15% | +175.86% |
07/06 | Kiromic Biopharma, Inc. Issues 25% Senior Secured Convertible Promissory Note | CI |
03/06 | Kiromic BioPharma, Inc. announced that it has received $2 million in funding | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+175.86% | 5.07M | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- KRBP Stock
- News Kiromic BioPharma, Inc.
- Kiromic BioPharma, Inc. Reports Favorable Deltacel Preclinical Pharmacology Results